Viatris (VTRS) Competitors $9.99 +0.02 (+0.20%) Closing price 10/9/2025 04:00 PM EasternExtended Trading$9.99 +0.00 (+0.04%) As of 04:25 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VTRS vs. PFE, ARGX, ONC, INSM, BNTX, TEVA, GMAB, SMMT, ASND, and RDYShould you be buying Viatris stock or one of its competitors? The main competitors of Viatris include Pfizer (PFE), argenex (ARGX), BeOne Medicines (ONC), Insmed (INSM), BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), Summit Therapeutics (SMMT), Ascendis Pharma A/S (ASND), and Dr. Reddy's Laboratories (RDY). These companies are all part of the "medical" sector. Viatris vs. Its Competitors Pfizer argenex BeOne Medicines Insmed BioNTech Teva Pharmaceutical Industries Genmab A/S Summit Therapeutics Ascendis Pharma A/S Dr. Reddy's Laboratories Pfizer (NYSE:PFE) and Viatris (NASDAQ:VTRS) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, media sentiment, analyst recommendations and earnings. Is PFE or VTRS a better dividend stock? Pfizer pays an annual dividend of $1.72 per share and has a dividend yield of 6.8%. Viatris pays an annual dividend of $0.48 per share and has a dividend yield of 4.8%. Pfizer pays out 91.5% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Viatris pays out -16.6% of its earnings in the form of a dividend. Pfizer has increased its dividend for 16 consecutive years. Pfizer is clearly the better dividend stock, given its higher yield and longer track record of dividend growth. Does the media prefer PFE or VTRS? In the previous week, Pfizer had 98 more articles in the media than Viatris. MarketBeat recorded 101 mentions for Pfizer and 3 mentions for Viatris. Viatris' average media sentiment score of 1.09 beat Pfizer's score of 1.04 indicating that Viatris is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pfizer 63 Very Positive mention(s) 11 Positive mention(s) 17 Neutral mention(s) 4 Negative mention(s) 2 Very Negative mention(s) Positive Viatris 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals hold more shares of PFE or VTRS? 68.4% of Pfizer shares are owned by institutional investors. Comparatively, 79.9% of Viatris shares are owned by institutional investors. 0.1% of Pfizer shares are owned by insiders. Comparatively, 0.1% of Viatris shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Do analysts prefer PFE or VTRS? Pfizer presently has a consensus target price of $28.41, indicating a potential upside of 12.66%. Viatris has a consensus target price of $10.40, indicating a potential upside of 4.10%. Given Pfizer's stronger consensus rating and higher possible upside, research analysts clearly believe Pfizer is more favorable than Viatris.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pfizer 1 Sell rating(s) 12 Hold rating(s) 4 Buy rating(s) 2 Strong Buy rating(s) 2.37Viatris 3 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.67 Is PFE or VTRS more profitable? Pfizer has a net margin of 16.84% compared to Viatris' net margin of -24.57%. Pfizer's return on equity of 21.42% beat Viatris' return on equity.Company Net Margins Return on Equity Return on Assets Pfizer16.84% 21.42% 9.12% Viatris -24.57%16.54%7.06% Which has more risk and volatility, PFE or VTRS? Pfizer has a beta of 0.55, indicating that its stock price is 45% less volatile than the S&P 500. Comparatively, Viatris has a beta of 0.9, indicating that its stock price is 10% less volatile than the S&P 500. Which has preferable valuation & earnings, PFE or VTRS? Pfizer has higher revenue and earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPfizer$63.63B2.25$8.03B$1.8813.41Viatris$14.74B0.79-$634.20M-$2.90-3.44 SummaryPfizer beats Viatris on 15 of the 20 factors compared between the two stocks. Get Viatris News Delivered to You Automatically Sign up to receive the latest news and ratings for VTRS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VTRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VTRS vs. The Competition Export to ExcelMetricViatrisMedical Services IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.62B$8.14B$6.15B$10.64BDividend Yield4.81%2.13%5.66%4.69%P/E Ratio-3.4475.6385.9927.64Price / Sales0.7938.74628.97141.97Price / Cash1.9622.9538.3262.20Price / Book0.646.9312.956.79Net Income-$634.20M$247.60M$3.30B$275.88M7 Day Performance-1.96%-1.44%3.69%1.84%1 Month Performance-2.44%1.47%10.68%8.84%1 Year Performance-11.83%11.74%83.35%36.10% Viatris Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VTRSViatris1.8207 of 5 stars$9.99+0.2%$10.40+4.1%-12.4%$11.62B$14.74B-3.4432,000Positive NewsAnalyst ForecastPFEPfizer4.9596 of 5 stars$23.84+0.3%$28.12+17.9%-16.5%$135.54B$63.63B12.6881,000Trending NewsDividend AnnouncementAnalyst ForecastOptions VolumeARGXargenex3.6767 of 5 stars$719.04+1.0%$789.20+9.8%+54.6%$44.01B$2.25B36.871,599Analyst ForecastONCBeOne Medicines1.4898 of 5 stars$332.83+2.1%$336.30+1.0%N/A$36.48B$3.81B-192.3911,000Positive NewsAnalyst ForecastINSMInsmed3.2143 of 5 stars$141.65+3.4%$139.86-1.3%+135.0%$29.94B$363.71M-24.811,271Analyst ForecastBNTXBioNTech2.4102 of 5 stars$98.10+0.0%$134.56+37.2%-11.1%$23.58B$2.98B-61.316,772Positive NewsTEVATeva Pharmaceutical Industries3.1086 of 5 stars$19.17+4.5%$25.14+31.2%+13.1%$21.99B$16.54B-119.8136,830Analyst ForecastAnalyst RevisionGMABGenmab A/S4.2433 of 5 stars$29.33+0.9%$40.00+36.4%+34.7%$18.82B$3.12B14.742,682Analyst ForecastHigh Trading VolumeSMMTSummit Therapeutics3.1041 of 5 stars$21.16+1.0%$31.29+47.9%+19.8%$15.72B$700K-20.95110Analyst ForecastASNDAscendis Pharma A/S3.0121 of 5 stars$191.60-0.2%$244.36+27.5%+66.1%$11.81B$393.54M-37.131,017News CoveragePositive NewsAnalyst ForecastRDYDr. Reddy's Laboratories3.0515 of 5 stars$13.96-1.9%$16.95+21.5%-10.1%$11.65B$3.81B21.1427,811Analyst Forecast Related Companies and Tools Related Companies Pfizer Alternatives argenex Alternatives BeOne Medicines Alternatives Insmed Alternatives BioNTech Alternatives Teva Pharmaceutical Industries Alternatives Genmab A/S Alternatives Summit Therapeutics Alternatives Ascendis Pharma A/S Alternatives Dr. Reddy's Laboratories Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VTRS) was last updated on 10/10/2025 by MarketBeat.com Staff From Our Partners"I'm risking my reputation on this"The Fed rate cut truth they don't want you to know The Fed's 25 basis point cut isn't just monetary policy…...Crypto 101 Media | SponsoredRobinhood warningA strange chasm is coming to Wall Street... It's already creating millionaires and billionaires at the fast...Stansberry Research | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredTrump to get REVENGE on the banks??Rumors are swirling that Trump could target the banking system by upending the $5 trillion-a-day SWIFT network...The Oxford Club | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredToo busy for AI trading?Last week, Nvidia and AMD stock soared as export restrictions eased. Nvidia alone gained nearly 5% in a sin...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viatris Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Viatris With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
